Audit: QRS - PEITC for Health & Longevity

Audit conducted on 22/08/2026 04:12 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol doses, gate items, tier contents, markers, targets and cadence trace to ER text.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“never looked for in people”, “Measured in one trial only”, “No target; track change from own baseline” mirror ER hedging.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain absolute; interactions remain interactions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates come from Key Interactions & Contraindications; tiers from Expected Benefits / Potential Risks & Side Effects; no cross-category migration.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Same flat, declarative, non-promotional register as the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Presents actionable doses, genotype gate, and testable markers without hype or alarm.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	States what trials used and what markers show, not what to do.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; cadence and markers are descriptive.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “should”, “advised” in the QRS voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to biomarker and drug-class names where no plain equivalent exists.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits and risks reduced to bare ER headings; gate items stripped to the key fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by scan: no “you”, “your”, “yourself”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Genotype testing, urinary mercapturic acid assays and cycling all presuppose this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Four-times-daily dosing and specialist research-lab assays are presented without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No consumer-simplified “just eat more vegetables” framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance foregrounds the GSTM1/GSTT1 responder split and the unstudied rodent bladder signal.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“transaminases”, “hematuria”, “urinary retention”, “mercapturic acids” used throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate heads, tier labels and column headers match the template byte for byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; repeatable marker_#* and qualitative_item# expanded to 10 and 5 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans and all CSS are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard investigational dose”, “Whole-food alternative”, “Culinary alternative”, “Tolerability”, “Urinary symptoms”, “Energy and cognitive clarity”, “Adherence”, “Thyroid symptoms” all verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Detoxification endpoints”, “DNA-damage endpoints”, “Clinical endpoints”) are taken verbatim from ER Practical Considerations.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Confirmed by scan: no emoji code points in the file.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against the ER: benefits and risks reduced to headings only, drug lists trimmed, monitoring rationales shortened to fragments.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- line 3, closing --- line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no duplicate on the page.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: peitc_2026-0822-0231_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0822-0338.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: peitc_2026-0822-0231_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All nine keys clean; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “PEITC for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “PEITC for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/22/2026”, matching qrs_creation_date: 2026-0822-0338.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only title and the template subline.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Covers what it is, the dosing shape, the measured effect, the responder split, and the counterweight risk.
7.2	[at_a_glance] is no longer than 60 words	🟢	50 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct sentence of ER Conclusion (lines 512–516).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “detoxification genes” replaces GSTM1/GSTT1, “harmful inhaled chemicals” replaces the named volatiles.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No percentages, ratios or p-values.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the ER’s “Populations who should avoid PEITC” list (ER lines 341–348).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete 1:1 coverage of the eight ER bullets, including the chemotherapy/radiotherapy absolute contraindication.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements, lines 567–574.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationales (“given the rodent promotion signal”, “who were excluded from every trial”) are stripped; no dashes carry trailing clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	”(<100 µg/L)”, “(eGFR <30 mL/min/1.73 m²)”, “(Child-Pugh C)”, “>3× upper limit”, “stage 4+”, “under 18” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names eight such populations and the section is correctly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items map to the ER’s interaction bullets (ER lines 315–337).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eleven of the ER’s twelve bullets carried; “Oxidative chemotherapy and radiotherapy” correctly excluded because it sits in Contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven <li> elements, lines 582–592.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER mitigation clauses (“Dose separation and level rechecks…”, “Separation by at least four hours…”) are all stripped; no dash-trailing content.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists retained and trimmed, never dropped: “(theophylline, caffeine)”, “(chlorzoxazone, ethanol)”, “(tacrolimus, digoxin, lithium)”, “(methimazole)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names twelve interactions and the section is correctly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol bullets at lines 374–378.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The ER’s three general-population delivery routes are selected; the oncology-adjunct route is correctly omitted as out of audience scope.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Labels verbatim from ER bold labels; values and subs carry the ER’s doses, matrices and split-dosing detail.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Matches the three endpoints named in ER Practical Considerations line 435.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Detoxification (ER High tier) first, then DNA damage and clinical endpoints (ER Medium tier) in ER order.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“1–2 weeks / The shortest dosing period tested”, “8 weeks”, “12 weeks / Measured in one trial only” all trace to the ER.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten benefit headings from ER lines 161–219 are represented in their ER tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated, lines 533–557.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare ER sub-heading; no Magnitude figures, p-values or study descriptions carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight risk headings from ER lines 247–293 are represented in their ER tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated, lines 604–623.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare ER sub-heading; rodent dose percentages and relative risks are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table and cadence both trace to ER Monitoring Protocol & Defining Success (ER lines 463–478).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER table rows are present in ER order, with targets preserved.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 754: baseline, eight-week recheck, cycle-end/six-monthly, four-week drug levels, two-week mercapturic acids — all from ER lines 463–476.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER’s qualitative marker list (ER lines 482–486).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Tolerability, urinary symptoms, energy and cognitive clarity, adherence, and thyroid symptoms — five of five.

Issues 22/08/2026 04:12

Pass rate 100.00%. No issues found.

Issues 22/08/2026 04:09

1. 8.5 — Transaminase threshold referent dropped: Line 572 renders the ER’s “transaminases above three times the upper limit of normal” (ER line 346) as “transaminases >3×”, dropping the referent entirely and leaving a multiplier with nothing to multiply.
2. 4.3 — Biomarker label abbreviated: Line 718 uses “Urinary mercapturic acids (acrolein, benzene)” instead of the ER’s biomarker label “Urinary mercapturic acids of acrolein and benzene” (ER line 476).

Fixes 22/08/2026 04:09

1. 8.5 — Transaminase threshold referent restored: Changed the Contraindications item from “transaminases >3×” to “transaminases >3× upper limit”, restoring the referent the ER’s threshold depends on.
2. 4.3 — Biomarker label restored verbatim: Changed [marker_8_name] from “Urinary mercapturic acids (acrolein, benzene)” to the ER’s label “Urinary mercapturic acids of acrolein and benzene”.

Issues 22/08/2026 04:02

1. 1.3 — Contraindication qualifiers dropped: Stop item 2 (line 568) reads “Interstitial cystitis, hematuria, urinary retention”, dropping the ER’s “active”, “recurrent” and “chronic” qualifiers (ER line 342) and thereby broadening the gate beyond what the ER states.
2. 4.2 — Interaction labels not verbatim: “Narrow-index drugs” (line 585), “Over-the-counter PPIs and antacids” (line 588) and “Other NRF2 activators (curcumin, resveratrol)” (line 592) restate rather than reproduce the ER bold labels at ER lines 321, 329 and 337.
3. 4.3 — Labels abbreviated or invented: “PPIs” (line 588) is an abbreviation the ER never uses, “high-dose antioxidants” (line 589) shortens the ER’s “high-dose antioxidant supplements”, and “NRF2 activators” replaces the ER’s “NRF2-activating botanicals” while dropping milk thistle entirely.

Fixes 22/08/2026 04:02

1. 1.3 — Contraindication qualifiers restored: Stop item 2 changed from “Interstitial cystitis, hematuria, urinary retention” to “Active interstitial cystitis, recurrent hematuria, chronic retention”, restoring the ER’s severity qualifiers.
2. 4.2 / 4.3 — Narrow-index label restored: “Narrow-index drugs (tacrolimus, digoxin, lithium)” changed to “Narrow-therapeutic-index agents (tacrolimus, digoxin, lithium)”, matching the ER bold label.
3. 4.2 / 4.3 — PPI abbreviation expanded: “Over-the-counter PPIs and antacids” changed to “Over-the-counter proton-pump inhibitors, antacids”, removing an abbreviation the ER never uses.
4. 4.3 — Antioxidant supplements restored: “N-acetylcysteine, glutathione, high-dose antioxidants” changed to “N-acetylcysteine, glutathione, high-dose antioxidant supplements”.
5. 4.2 / 4.3 — NRF2 botanicals label restored: “Other NRF2 activators (curcumin, resveratrol)” changed to “Milk thistle, curcumin, resveratrol, other NRF2-activating botanicals”, reinstating milk thistle and the ER’s wording.

Issues 22/08/2026 03:52

1. 4.5 — One-page budget exceeded: No per-section condensation was applied; the Contraindications gate wraps to roughly 15 lines and Key Interactions to roughly 17 at 9.5pt in half-width columns, so header through gates alone fills the A4 body and pushes Risks, Monitoring, and Qualitative Assessment onto a second page.
2. 9.5 — “Over-the-counter” qualifier dropped: The distinguishing qualifier from ER lines 327 and 329 is missing, leaving a bare “Acetaminophen” on line 590 that duplicates the drug already named in the CYP2E1 substrates item on line 586.

Fixes 22/08/2026 03:52

1. 9.5 — Over-the-counter qualifier restored: Restored the ER’s distinguishing qualifier on the two over-the-counter bullets, changing “Acetaminophen” to “Over-the-counter acetaminophen” and “Proton-pump inhibitors and antacids” to “Over-the-counter PPIs and antacids”, so the acetaminophen item no longer reads as a bare duplicate of the CYP2E1 substrates entry.
2. 4.5 — Contraindications gate condensed: Trimmed the eight stop items from roughly 15 wrapped lines to 13, dropping the example-drug parenthetical from the chemotherapy/radiotherapy item and tightening the bladder, cystitis, thyroid, kidney, and liver entries while keeping every threshold and staging qualifier.
3. 4.5 — Key Interactions gate condensed: Trimmed the eleven caution items from roughly 17 wrapped lines to 11 by shortening the example drug lists (CYP1A2, CYP2E1, narrow-index, antithyroid, NRF2 activators) rather than dropping any item, per 9.5’s allowance for budget trimming.
4. 4.5 — Protocol sub-cells condensed: Shortened action_2_sub to “Freeze-dried watercress drink, three divided doses; larger effect than the isolate” and action_3_sub to “Two cups of loose leaves; raw, since boiling destroys the converting enzyme”, removing one wrapped line from each and reducing the protocol grid row height.

Issues 22/08/2026 03:44

1. 4.5 / 2.8 — Sheet overruns one A4 page: The populated sheet stacks to roughly 1950px against ~1030px of printable A4 height (Monitoring alone ~573px across ten rows plus a four-sentence cadence), so it renders onto a second page instead of being condensed to the per-section budget.
2. 2.8 — Verbatim ER prose left uncondensed: The Monitoring “why” cells (lines 655-754), the cadence sentence (lines 762-765) and the five Qualitative Assessment items (lines 774-802) reproduce full ER sentences rather than compact phrases, and several Contraindication items restate the ER bullet at full length.

Fixes 22/08/2026 03:44

1. 4.5 / 2.8 — Monitoring table condensed: All ten “why” cells and six “target” cells were cut to compact phrases (e.g. “Tracks the systemic inflammation endpoint the one human trial failed to move” → “Systemic inflammation endpoint unmoved in trial”; “Below 25 U/L (men), below 20 U/L (women)” → “<25 U/L (men), <20 U/L (women)”), removing roughly a quarter of the table’s rendered height while keeping all ten biomarkers.
2. 2.8 — Cadence reduced to one compact line: The four-sentence verbatim ER paragraph was rewritten as a single condensed sequence using the abbreviations already established in the Monitoring table (“Thyroid-stimulating hormone, free thyroxine, and urinalysis repeated at eight weeks…” → “TSH, free T4, urinalysis at eight weeks, then each cycle end or six-monthly…”).
3. 2.8 — Qualitative Assessment explanations stripped: Four of the five items lost their trailing ER rationale clauses (e.g. Thyroid symptoms no longer carries “which would suggest thyroid drift before it appears in bloodwork”), leaving the bold label plus the observable signs.
4. 4.5 / 2.8 — Contraindication items tightened: Six of the eight items were shortened with every threshold and staging qualifier preserved (e.g. “Chronic kidney disease at stage 4 or worse (eGFR below 30 mL/min/1.73 m²)” → “Chronic kidney disease stage 4+ (eGFR <30 mL/min/1.73 m²)”).
5. 4.5 — Key Interaction items tightened: Redundant wording was dropped from six items while all named example drugs were retained (e.g. “Over-the-counter proton-pump inhibitors and antacids” → “Proton-pump inhibitors and antacids”; “Sulforaphane, broccoli sprout extract, and other isothiocyanate supplements” → “Sulforaphane and other isothiocyanate supplements”).
6. 4.5 — At-A-Glance and Protocol subs shortened: The at-a-glance summary was cut from 58 to 50 words and the two longest protocol sub-lines were trimmed by a line each, without dropping any fact.